My NCBISign In
Print View 

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2011.

Bookshelf ID: NBK83300PMID: 22259815

89Zr-Desferrioxamine-anti-CD105 TRC105 chimeric monoclonal antibody

89Zr-Df-TRC105
Kam Leung, PhD
National for Biotechnology Information, NLM, NIH, Bethesda, MD
MICAD/at/ncbi.nlm.nih.gov

Created: November 1, 2011; Last Update: January 12, 2012.

Chemical name:89Zr-Desferrioxamine-anti-CD105 TRC105 chimeric monoclonal antibody
Abbreviated name:89Zr-Df-TRC105
Synonym:
Agent category:Antibody
Target:CD105 (Endoglin, EDG)
Target category:Antigen
Method of detection:Positron emission tomography (PET)
Source of signal/ contrast:89Zr
Activation:No
Studies:

  • Checkbox In vitro

  • Checkbox Rodents

Click on protein, nucleotide (RefSeq), and gene for more information about CD105

Background

Go to:

[PubMed]

Angiogenesis is an essential process in the development of new blood vessels both in normal physiological states and diseases (1, 2). Targeting of tumor vasculature is a promising strategy for tumor imaging and therapy because tumor growth and metastasis largely depend on angiogenesis (3-5). Transforming growth factor-β (TGF-β) is a pleiotropic cytokine that modulates blood vessel development, angiogenesis, and tumor progression (6). There are three isoforms of TGF-β (β1, β2, and β3). TGF-β1 inhibits proliferation and migration of endothelial cells and their ability to form capillaries. CD105 (endoglin, EDG) is a homodimeric transmembrane glycoprotein (180 kDa) with disulfide-linked subunits of 95 kDa. CD105 is a component of the TGF-β receptor complex that specifically binds TGF-β1 and TGF-β3 with high affinity (7). CD105 is important for blood vessel development. The expression of CD105 on different cells affects cellular response to TGF-β1. CD105 is overexpressed in proliferating endothelial cells of tumor vessels, and CD105 prevents TGF-β1-mediated inhibition of endothelial cell proliferation (8, 9).

Radiolabeled monoclonal antibodies (mAbs) have been developed for both the diagnosis and treatment of tumors (10-12). Quiescent human endothelial cells express CD105 only weakly, but the expression of CD105 is strongly upregulated on the endothelial cells of tumor tissues undergoing angiogenesis (9, 13). Anti-CD105 mAbs, such as MAEND3, E9, and MJ7/18 with radioisotopes (e.g., 111In, 99mTc, and 125I) have been studied as single-photon emission computed tomography (SPECT) probes for imaging CD105 expression (9, 14). TRC105 is a human/murine chimeric IgG1 mAb that binds with higher affinity to human CD105 than to murine CD105 (15). TRC105 inhibits angiogenesis and tumor growth and is now in clinical trials in cancer patients. Hong et al. (16) showed that 64Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-anti-CD105 TRC105 (64Cu-DOTA-TRC105) mAbs could efficiently image 4T1 murine breast tumor in mice with positron emission tomography (PET) imaging. Hong et al. (17) also evaluated 89Zr-desferrioxamine-TRC105 (89Zr-Df-TRC105) as a 89Zr-based PET agent in the same 4T1 murine breast tumor model.

Synthesis

Go to:

[PubMed]

Df-TRC105 was prepared by conjugation of p-isothiocyanatobenzyl-desferrioxamine B to TRC105 at a molar ratio of 3:1 (pH 9) (17). Df-TRC105 was purified with column chromatography. The number of Df moieties per mAb was not reported. Df-TRC105 was incubated with 89Zr-oxalate in HEPES buffer (pH 7) for 60 min at 25°C. 89Zr-Df-TRC105 was purified with column chromatography. This procedure provided a radiolabeling yield of 62 ± 15% (n = 10) with a specific activity of ~74 MBq/nmol (2 mCi/nmol) and a radiochemical purity of >95%. The total preparation time was ~100 min. 89Zr-Df-cetuximab was also prepared similarly as an isotype-matched control with similar specific activity. Cetuximab is an anti-EGFR mouse-human chimeric IgG1 mAb.

In Vitro Studies: Testing in Cells and Tissues

Go to:

[PubMed]

Hong et al. (17) performed in vitro indirect fluorescence staining with the unlabeled TRC105 and Df-TRC105 on MCF7 human breast cancer cells (CD105-negative) and human umbilical vein endothelial cells (HUVECs, CD105-positive). Fluorescence microscopy and flow cytometry showed strong CD105 expression in HUVECs but weak or no expression in MCF7 cells. No significant differences in fluorescence intensities between TRC105 and Df-TRC105 were observed in the HUVEC cells, suggesting that Df-TRC105 retains immunoreactivity similar to that of the unconjugated mAb. 89Zr-Df-TRC105 was >95% intact in mouse serum after incubation for 7 days at 37°C.

Animal Studies

Go to:

Rodents

[PubMed]

Hong et al. (17) injected 5–10 MBq (0.14–0.27 mCi) 89Zr-Df-TRC105 into mice bearing the CD105-positive 4T1 murine breast tumors for ex vivo biodistribution and PET imaging studies (n = 4/group). Ex vivo tumor accumulation was 13% injected dose/gram (ID/g) and 6% ID/g at 24 h and 96 h after injection, respectively. The tumor/muscle ratio was 24.8 ± 4.3 at 96 h. The organ with the highest accumulation at 24 h was the liver (9% ID/g), followed by the kidney (6% ID/g), lung (4% ID/g), and spleen (3% ID/g). By 96 h, tumor accumulation was higher than that in all major organs. The radioactivity level in the blood decreased from 6.5% ID/g at 24 h to ~2.5% ID/g at 96 h. On the other hand, the accumulation of 89Zr-Df-cetuximab at 96 h after injection was higher or similar to that of 89Zr-Df-TRC105 in most organs except in the 4T1 tumors. The tumor accumulation of 89Zr-Df-cetuximab at 96 h after injection was 40% of 89Zr-Df-TRC105 tumor accumulation (P < 0.05). Injection of excess TRC105 (13 nmol) 2 h before 89Zr-Df-TRC105 inhibited tumor and blood radioactivity levels to the background level (<1% ID/g) at 96 h after injection. In contrast, there was a two-fold increase in liver accumulation of 89Zr-Df-TRC105 (P < 0.01). Immunofluorescence staining of 4T1 tumor sections showed colocalization of CD31 with CD105 on the tumor endothelial cells (CD31- and CD105-positive) but not on tumor cells (CD31-negative, CD105-positive). On the other hand, there was only weak CD105 staining on the liver and spleen sections. There was some staining in the capillaries in the medulla of the kidney sections. The accumulation of 89Zr-Df-TRC105 in the 4T1 tumors was largely CD105 specific, whereas accumulation in the liver and spleen was largely CD105 nonspecific.

PET imaging revealed estimated tumor accumulation of 6.1 ± 1.2% ID/g, 14.3 ± 1.2% ID/g, 12.4 ± 1.5% ID/g, 7.1 ± 0.9% ID/g, and 5.2 ± 0.3% ID/g at 5, 24, 48, 72, and 96 h after injection of 89Zr-Df-TRC105, respectively. Accumulation in the liver was 12.4 ± 2.1% ID/g at 5 h and declined gradually to 2.3 ± 0.1% ID/g at 96 h. The radioactivity in the blood was 14.7 ± 2.5% ID/g at 5 h and declined to 2.0 ± 0.4% ID/g at 96 h. The tumor accumulation of 89Zr-Df-cetuximab was <3% ID/g at 5–96 h after injection. Injection of excess TRC105 (13 nmol) 2 h before 89Zr-Df-TRC105 inhibited tumor accumulation to the background level (<2% ID/g) at all the time points examined. In contrast, there was a one- to two-fold increase in the radioactivity in the liver, and the radioactivity in the blood was <1% ID/g at 5–96 h after injection.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

Go to:

[PubMed]

No publication is currently available.

References

Go to:
1.
Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. [PubMed: 21593862]
2.
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31. [PubMed: 7584949]
3.
Fonsatti E., Altomonte M., Arslan P., Maio M. Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets. 2003;4(4):291–6. [PubMed: 12699349]
4.
Abdollahi A., Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat. 2010;13(1-2):16–28. [PubMed: 20061178]
5.
Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10(2):415–27. [PubMed: 14760060]
6.
Massague J., Cheifetz S., Laiho M., Ralph D.A., Weis F.M., Zentella A. Transforming growth factor-beta. Cancer Surv. 1992;12:81–103. [PubMed: 1638549]
7.
Cheifetz S., Bellon T., Cales C., Vera S., Bernabeu C., Massague J., Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267(27):19027–30. [PubMed: 1326540]
8.
Tabata M., Kondo M., Haruta Y., Seon B.K. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int J Cancer. 1999;82(5):737–42. [PubMed: 10417773]
9.
Bredow S., Lewin M., Hofmann B., Marecos E., Weissleder R. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. Eur J Cancer. 2000;36(5):675–81. [PubMed: 10738134]
10.
Wu A.M., Senter P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137–46. [PubMed: 16151407]
11.
Milenic D.E., Brechbiel M.W. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther. 2004;3(4):361–70. [PubMed: 14976424]
12.
Kowalsky, R.J., S.W. Falen, Radiopharmaceutcals in nuclear pharmacy and nuclear medicine. Second ed. 2004, Washington, D.C.: APhA. 733-752.
13.
Seon B.K., Haba A., Matsuno F., Takahashi N., Tsujie M., She X., Harada N., Uneda S., Tsujie T., Toi H., Tsai H., Haruta Y. Endoglin-targeted cancer therapy. Curr Drug Deliv. 2011;8(1):135–43. [PubMed: 21034418]
14.
Fonsatti E., Jekunen A.P., Kairemo K.J., Coral S., Snellman M., Nicotra M.R., Natali P.G., Altomonte M., Maio M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res. 2000;6(5):2037–43. [PubMed: 10815930]
15.
Tsujie M., Tsujie T., Toi H., Uneda S., Shiozaki K., Tsai H., Seon B.K. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer. 2008;122(10):2266–73. [PubMed: 18224682]
16.
Hong H., Yang Y., Zhang Y., Engle J.W., Barnhart T.E., Nickles R.J., Leigh B.R., Cai W. Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging. 2011;38(7):1335–43. [PMC free article: PMC3105181] [PubMed: 21373764]
17.
Hong, H., G.W. Severin, Y. Yang, J.W. Engle, Y. Zhang, T.E. Barnhart, G. Liu, B.R. Leigh, R.J. Nickles, and W. Cai, Positron emission tomography imaging of CD105 expression with (89)Zr-Df-TRC105. Eur J Nucl Med Mol Imaging, 2011.

Copyright Notice: http://www.ncbi.nlm.nih.gov/books/about/copyright/

Print View 
Cover of Molecular Imaging and Contrast Agent Database (MICAD)
Molecular Imaging and Contrast Agent Database (MICAD) [Internet].

Download

In this page

About MICAD

Search MICAD

Limit my Search:

In vitro Rodents Non-primate non-rodent mammals
Non-human primates Humans Any

Related information

Related citations in PubMed

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > Bookshelf
Write to the Help Desk